phase-i

A collection of 6 issues

c-Met antibody-drug conjugate receives FDA breakthrough designation for refractory metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT c-Met antibody-drug conjugate receives FDA breakthrough designation for refractory metastatic CRC Telisotuzumab adizutecan, a c-Met–directed antibody-drug conjugate, received FDA breakthrough therapy designation in combination with bevacizumab for adults with refractory metastatic colorectal cancer who have previously received fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF

Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition

Skip to content The CRC Digest ▸ TREATMENT Case report: BRAF V600E-mutant metastatic CRC patient achieves prolonged response to combined BRAF and MEK inhibition A 60-year-old male patient diagnosed in 2019 with BRAF-mutant metastatic CRC and peritoneal metastases experienced an extraordinary response to MEK inhibitor-based treatment. (Frontiers in Oncology) This content

Subscribe to The CRC Digest

Sign up now to get access to the library of members-only issues.
jamie@example.com
Subscribe